Drug-Coated Balloons:

Slides:

Advertisements

Similar presentations

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

Advertisements

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.

TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.

APS. Investigators & Sites APS Background Study Hypotheses.

12-Month Analysis Barry T. Katzen MD, FACR, FACC Founder and Medical Director Baptist Cardiac & Vascular Institute.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

A Comparison of the Moxy™ Drug Coated Balloon Catheter vs. Standard PTA for Femoropopliteal Disease NCT# MONTH RESULTS OF THE LEVANT I TRIAL.

UpdateDEB Lesions Learned from the Trials and Daily Clinical Practice Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden.

Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Global Experience with Peripheral DCBs/Stent Studies: C.R. Bard

Lutonix® Paclitaxel-Coated Balloon to Treat Obstructive Lesions in the Superficial Femoral and Popliteal Arteries Preliminary Six-Month Results from.

DCB Potential Beyond the Selected SFA Lesions Types Studied in Trials to Date What We Know About the ‘Real World’ Krishna Rocha-Singh, MD Chief Scientific.

The (Potential) Role of Drug Eluting Balloons in BTK Interventions

Fem-Pop Stenting: Is ZILVER PTX DES The “De Facto” Stent to Deploy?

PRESENTER NAME Waikato Cardiothoracic Unit Journal Club

Eric J Dippel, MD FACC Davenport, Iowa, USA February 19, 2017

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

Drug Eluting Balloons Bodo Cremers, MD

Drug-Coated Balloons in Peripheral Artery Disease

How the Latest Data in MDD Can Guide Treatment Decisions:

PCSK9 Inhibitors Post-CVOTs

Renal Denervation Two Late-Breaking Clinical Trials.

Panelists. Panelists Drug-Coated Balloon for PAD.

SIRIUS Trial: Diameter Restenosis

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

PAD Patients vs Post-ACS Patients:

The Safety and Efficacy of Full vs

Metastatic Renal Cell Carcinoma

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

New Treatments for CTEPH

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?

Efficacy and Safety of Edoxaban in Patients With AF and HF

Selected Highlights of the Latest Advances in PAH

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

ENDEAVOR IV: 5 Year Final Outcomes

ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.

Aspirin and Cardioprevention in 2018

T2DM Management.

Better Diabetes Control With Novel Basal Insulins

The American College of Cardiology Presented by Dr. Raimund Erbel

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty Nicholas Candy, MBBS, Eugene Ng, MBBS, Ramesh.

Drug-eluting stents for in-stent restenosis

Statins, Obesity, and Hyperlipidemia

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

Can Drug-Coated Balloons Be a Solution for Complex Peripheral Lesions?

Program Goals Background: Anticoagulation in Patients With VTE.

Elevated Admission Plasma Glucose Following ACS

Division of Endovascular Interventions

ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS

Long Term Clinical Results from the Endeavor Program: 5-Year Follow up

2015 EASD In Review: CV Risk management in t2dm

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

American College of Cardiology Presented by Dr. Adnan Kastrati

The American College of Cardiology Presented by Dr. A. Abazid

What's New in Oral Combination Therapy for Type 2 Diabetes?

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

Top Tips in Evidence-Based Care for HFrEF

Panelists. Panelists Drug-Coated Balloon for PAD.

Translating Data From Trial to Practice

Presentation transcript:

Drug-Coated Balloons:

Program Goals

Background

IN.PACT SFA Trial: Overview

IN.PACT SFA Trial: Primary Outcomes

IN.PACT SFA Trial: 4-Year Follow-up Assessment

IN.PACT SFA Trial: Baseline Characteristics

IN.PACT SFA Trial: Primary Patency Through 3 Years

IN.PACT SFA Trial: Freedom from CD-TLR Through 4 Years

IN.PACT SFA Trial: TLR Data Through 4 Years

IN.PACT SFA Trial: Independent Predictors of CD-TLR

IN.PACT SFA Trial: Safety Outcomes through 4 Years

IN.PACT SFA Trial: Summary

Timeline to Assess Effectiveness of Therapy

Approaches to Preventing Restenosis

IN.PACT Global: Study Architecture

IN.PACT Global: Primary Endpoints

IN.PACT Global: Key Eligibility Criteria

IN.PACT Global: Baseline Characteristics

IN.PACT Global: Lesion and Procedural Characteristics

IN.PACT Global: Freedom from CD-TLR Through 2 Years

IN.PACT Global: Additional Effectiveness Outcomes

IN.PACT Global: Safety Outcomes Through 2 Years

2-Year Outcomes Across IN.PACT Studies

IN.PACT Global: Summary

DCB and Calcified Lesions

Severe Calcium Lesions Associated with Late Lumen Loss

Vessel Preparation Can Improve Outcomes

Past, Present, and Future of DCBs

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)